# Alloy

Publishes more about its formulas than almost anyone here — concentrations, full ingredient lists, results labelled by measurement method — across four pages that between them contain no safety information at all, under four headings that promise it.

- **Canonical:** https://www.30plusskin.care/brands/alloy
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## The operation

- **Category:** TELEHEALTH · MENOPAUSE-SPECIALISED PRESCRIBING
- **Model:** Online intake reviewed by a menopause-trained physician, compounded and manufactured prescriptions delivered, with unlimited doctor access included.
- **Products assessed:** 6
- **Mean score:** 63/100
- **Mean disclosure score:** 38/100
- **Pricing:** See each offer and billing period in the product records
- **Brand site:** https://www.myalloy.com
- **TRADING NAME:** ALLOY
- **LEGAL ENTITY:** ALLOY, INC.
- **MODEL:** MENOPAUSE TELEHEALTH → COMPOUNDED AND MANUFACTURED Rx
- **RANGE ASSESSED:** 6 PRODUCTS
- **ACTIVE:** ESTRIOL — NO FDA-APPROVED FORM EXISTS IN THE US
- **ESTRIOL BY PRODUCT:** EYE 1% · BODY 0.2% · FACE UNSTATED
- **FORMULA DISCLOSURE:** FULL LISTS ON ALL THREE; CONCENTRATIONS ON TWO
- **SAFETY DISCLOSURE:** NO RISK NAMED IN VISIBLE COPY ON ANY OF 6 PAGES

## Verdict

Six products assessed. Alloy is a menopause company that also sells skincare, and that framing produces the best-argued rationale we have read. Skin ageing after menopause is substantially an estrogen-deficiency problem — roughly 30% of dermal collagen goes in the first five years — and almost nothing on the market treats it as one. M4 does, with topical estriol.

Two disclosures put it ahead of the field. The full ingredient list is published on the product page, which four compounding competitors refuse to do. And the efficacy claim rests on a stated placebo-controlled trial rather than the day-30 satisfaction surveys the rest of this category runs on. A control arm and a significance test is a different order of claim.

Then the page stops. It has a tab headed 'Safety Information' that contains a product description and an ingredient list and nothing else. Side effects, contra-indications, pregnancy and breast cancer each appear zero times, on a prescription estrogen sold specifically to women in perimenopause and menopause — the population in which hormone-sensitive cancer is most common and in which estrogen exposure is sometimes the thing being actively suppressed.

Two further gaps. The absorption reassurance is phrased more absolutely than the evidence supports and contradicts the product's own collagen mechanism: estriol cannot both stay on the surface of the skin and reach dermal fibroblasts. And estriol has no FDA-approved form in the United States, so M4 is compounded by definition — a word Alloy applies plainly to three weight-loss drugs one menu away and never to this.

## Patterns in the reviewed range

### 01 — A section headed Safety Information, containing none

The product page's third tab is labelled 'Safety Information'. Under it: what the product is, the ingredient list, who it is for, what you receive, and how to get a prescription. Searched across the whole page, side effects appear zero times, contra-indications zero, pregnancy zero and breast cancer zero. The failure is not that safety copy is missing; it is that it is missing from the place explicitly promising it.

### 02 — The rationale is the best in the register and the citation is absent

Menopausal collagen loss is cited accurately — about 30% in five years, then 2.1% a year — and the efficacy claim is placebo-controlled at twelve weeks, which no competitor matches. But the study is credited to nobody: no journal, authors, year, sample size or link. And '88% improvement in elasticity' never says whether that is 88% of subjects or an 88% change.

### 03 — An absorption claim stronger than the evidence, and than the mechanism

'Topical estriol stays on the surface of your skin and doesn't enter your bloodstream.' The conclusion it supports — no impact on blood estrogen levels — is defensible; controlled facial trials measured serum FSH, prolactin and estradiol and found no significant change. The mechanism as stated is not: a molecule that stayed on the surface could not reach the dermal fibroblasts the product claims to stimulate. 'No measurable change in serum levels' and 'does not enter the bloodstream' are different statements.

### 04 — Instruments were run, and only sometimes reported

The body study used Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D and published only the questionnaire: 97% agree, 95% felt, 84% saw, 79% saw. The eye product runs the same four instruments on n=34 and does it properly — 'up to 40% more elasticity' and 'up to 40% less crepiness on the eyelids' marked Based on Expert Assessment, '23% immediate boost in hydration' marked Based on Instrumentation. Labelling results by method is the best evidential practice in this register, and the same company omits it one product away.

### 05 — The strongest concentration is on the most permeable skin

Estriol runs 1% in the eye cream, 0.2% in the body treatment, and unstated in the face cream. The controlled facial trials underpinning the line's safety case used 0.3%. So the highest strength in the range goes on periorbital skin — the thinnest and most permeable on the face — at more than three times the studied concentration, with no rationale offered. The mitigation is real and unstated: the eye area is tiny, so absolute exposure is probably the range's smallest.

### 06 — The formulation work is better than the instructions

The rosacea cream is the best-made compounded product in this register: an anhydrous silicone and ester base, so no preservative is needed and none is present — a real advantage on skin most likely to react to one — with two penetration enhancers appropriate to delivering azelaic acid from a waterless vehicle, an airless pump, and a published 0.3 ml actuator volume that nothing else here provides. It then states no application frequency and no bottle size, so the most precise dose figure in the register cannot be turned into a daily dose. Every Alloy page arrives one number short of a claim you could check.

### 07 — The one product they do not compound is the one that scores

Four compounded preparations score 58, 59, 59 and 65. The Lash & Brow Serum — generic Latisse, bimatoprost 0.03% — scores 69, states its FDA approval accurately, names its brand equivalent, publishes its concentration and its 5 ml volume, and carries the company's first citations. None of that required extra diligence: dispensing an approved drug means the manufacturer has already established the facts, and the page's job shrinks to not contradicting them.

### 08 — Every page discloses a different subset, and none discloses safety

The eye cream publishes three concentrations, a full ingredient list and results attributed to measurement method. The body treatment publishes one concentration and a full list. The tretinoin cream publishes a 30 g fill weight and a pea-sized dose — the only Alloy claim we have been able to verify arithmetically — and no concentration for any of its three strengths. The face cream publishes a list and nothing else. No page supplies more than three of six basic disclosures, no two supply the same three, and all four Safety Information sections contain a product description.

### 09 — A retinoid sold to women who can still conceive, with nothing said

The tretinoin page contains zero mentions of pregnancy, breastfeeding, contraception or birth defects, and zero of irritation, peeling or sunscreen. Alloy sells exclusively to perimenopausal and menopausal women; perimenopause means ovulation continues and contraception is still advised. Topical tretinoin is a far lower risk than the oral drug and the honest warning is proportionate rather than alarming — which is what makes its complete absence harder to explain, not easier.

### 10 — Facial evidence, body application

The line's no-systemic-effect reassurance rests on trials that applied estriol to faces. The body treatment is indicated for chest, legs, arms, hands and knees. Concentration is not exposure — 0.2% over a third of the skin delivers considerably more hormone than 0.3% on a face — and the body page makes no absorption statement at all, gives no application quantity and no fill size. Alloy sells estradiol gel one menu away as systemic HRT, applied to arms and thighs, so transdermal body application is a route the company uses deliberately elsewhere.

### 11 — Compounded, and the word appears everywhere except here

No FDA-approved estriol product exists in the United States, so M4 is necessarily compounded. The page says 'prescription', 'bioidentical' and 'plant based', never 'compounded' — while Alloy's own navigation lists Compounded Semaglutide, Compounded Tirzepatide and Compounded Liraglutide. The company also states its physicians follow ACOG guidance, and ACOG's clinical consensus on compounded bioidentical hormone therapy is cautionary.

## Credit where it is due

- Publishes the full ingredient list on the product page — complete and INCI-style, which four compounding competitors decline to do.
- Bases its efficacy claim on a stated placebo-controlled trial rather than an uncontrolled satisfaction survey.
- Cites the menopausal collagen-loss figures accurately.
- Treats the actual cause of menopausal skin change rather than its surface symptoms.
- A twelve-week timeline that matches the trial window instead of undercutting it.
- Real prescription gating with a menopause-trained physician reviewing medical history.
- $50 a month including unlimited doctor access, free delivery and HSA/FSA eligibility.
- States that the product can be used alongside HRT, which the controlled data supports.
- Names a medical team and cites ACOG and The Menopause Society as the guidance it follows.

## Disclosure matrix

| Product | CONC. ON PAGE | CONC. FINDABLE | CONTRA-INDICATIONS | SIZE | SIDE EFFECTS |
| --- | --- | --- | --- | --- | --- |
| Alloy Rosacea Face Cream Rx | yes | yes | no | no | no |
| Alloy Lash & Brow Serum Rx | yes | yes | no | yes | no |
| Alloy M4 Eye Cream Rx | yes | yes | no | no | no |
| Alloy Tretinoin Face Cream Rx | no | no | no | yes | no |
| Alloy M4 Body Treatment Rx | yes | yes | no | no | no |
| Alloy M4 Face Cream Rx | no | no | no | no | no |

## Reviews

| No. | Product | Stance | Score | Price | Document |
| --- | --- | --- | --- | --- | --- |
| R-33 | Rosacea Face Cream Rx — Azelaic 17% + metronidazole 1.11% + ivermectin 0.88% | CONDITIONAL | 70/100 | $33 | /reviews/alloy-rosacea-face-cream-review |
| R-32 | Lash & Brow Serum Rx — Bimatoprost 0.03% — generic Latisse | CONDITIONAL | 69/100 | $58 | /reviews/alloy-lash-brow-serum-review |
| R-30 | M4 Eye Cream Rx — Estriol 1% + peptides | CAUTION | 65/100 | $30 | /reviews/alloy-m4-eye-cream-review |
| R-28 | M4 Face Cream Rx — Topical estriol | CAUTION | 59/100 | $50 | /reviews/alloy-m4-face-cream-review |
| R-31 | Tretinoin Face Cream Rx — Tretinoin + niacinamide + aloe · three unnamed strengths | CAUTION | 59/100 | $30 | /reviews/alloy-tretinoin-face-cream-review |
| R-29 | M4 Body Treatment Rx — Estriol 0.2% + peptides | CAUTION | 58/100 | $65 | /reviews/alloy-m4-body-treatment-review |

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._